Phthisiology

doi: 10.25005/2074-0581-2022-24-2-204-217
IMPLEMENTATION STUDY IN PREVENTION AND CONTROL OF DRUG-RESISTANT TUBERCULOSIS DURING THE COVID-19 PANDEMIC IN DUSHANBE

Z.KH. TILLOEVA

City Center for Protection of Population from Tuberculosis, Dushanbe, Republic of Tajikistan

Objective: To assess an implementation study (IS) aimed at improving the epidemiological surveillance of tuberculosis (TB) and drug-resistant TB (DRTB) in Dushanbe during the COVID-19 pandemic.

Methods: IS assessment was carried out according to the RE-AIM framework and WHO recommendations for reporting on IS. To assess the effectiveness of the action taken, official statistics and reports from the City Center for Protection of Population from Tuberculosis were used.

Results: IS was a qualitative study. The study was supported by the WHO Special Program for Research and Training in Tropical Diseases (TDR). A multidisciplinary team led by the Dushanbe City Health Department has undertaken the following measures: introduction of a system of weekly epidemiological surveillance for TB at the primary health care (PHC) level from the second week of 2021; involvement of students of basic and advanced field epidemiology programs (FETP) in the assessment of the TB epidemiological surveillance system; tracking of registered patients with laboratory confirmation of TB; application of data from the quarterly reports in tracking the diagnostic trends and evaluation of the effectiveness of DR-TB treatment. All materials received were documented and used to train TB doctors and PHC workers. Only 66% of TB doctors were involved in capacity building in Dushanbe PHC: 24.4% of PHC workers were trained in the basics of TB diagnosis and treatment. Stabilization of TB and DR-TB rate was achieved in 2021 compared to 2020 (morbidity growth rates were 2.7% and 11.9%, respectively); effectiveness of treatment of TB with preserved sensitivity of M. tuberculosis (MBT) to anti-TB drugs in the 2020 cohort increased, but efficacy of DR-TB treatment in the 2019 cohort decreased.

Conclusion: IS has identified major barriers to achieving the TB elimination goals. Although the data indicate stabilization of TB and DR-TB incidence rates and increased effectiveness of drug-sensitive TB treatment in Dushanbe, further monitoring and achievement of sustainable results are required.

Keywords: COVID-19, tuberculosis, drug resistance, implementation study, TDR.

Download file:


References
  1. Cilloni L, Fu H, Vesga JF, Dowdy D, Pretorius C, Ahmedov S, et al. The potential impact of the COVID-19 pandemic on the tuberculosis epidemic a modelling analysis. EClinicalMedicine. 2020;28:100603. Available from: https://doi. org/10.1016/j.eclinm.2020.100603
  2. Chen L, Fu X, Tian P, Li Q, Lei D, Peng Z, et al. Upward trends in new, rifampicin- resistant and concurrent extrapulmonary tuberculosis cases in northern Guizhou Province of China. Sci Rep. 2021;11(1):18023. Available from: https:// doi.org/10.1038/s41598-021-97595-8
  3. Ding W, Li Y, Bai Y, Li Y, Wang L, Wang Y. Estimating the effects of the COVID-19 outbreak on the reductions in tuberculosis cases and the epidemiological trends in China: A causal impact analysis. Infect Drug Resist. 2021;14:4641-55. Available from: https://doi.org/10.2147/IDR.S337473
  4. Dara M, Kuchukhidze G, Yedilbayev A, Perehinets I, Schmidt T, Van Grinsven WL, et al. Early COVID-19 pandemic's toll on tuberculosis services, WHO European Region, January to June 2020. Euro Surveill. 2021;26(24):2100231. Available from: https://doi.org/10.2807/1560-7917.ES.2021.26.24.2100231
  5. Jeremiah C, Petersen E, Nantanda R, Mungai BN, Migliori GB, Amanullah F, et al. The WHO Global Tuberculosis 2021 Report – not so good news and turning the tide back to end TB. Int J Infect Dis. 2022:S1201-9712(22)00149-7. Available from: https://doi.org/10.1016/j.ijid.2022.03.011
  6. Makhmudova M, Maxsumova Z, Rajabzoda A, Makhmadov A, van den Hof S, Mirtskhulava V. Risk factors for unfavourable treatment outcomes among rifampicin-resistant tuberculosis patients in Tajikistan. Int J Tuberc Lung Dis. 2019;23(3):331-6. Available from: https://doi.org/10.5588/ijtld.18.0311
  7. Scott C, Mangan J, Tillova Z, Jensen PA, Ahmedov S, Ismoilova J, et al. Evaluation of the Tuberculosis Infection Control Training Center, Tajikistan, 2014- 2015. Int J Tuberc Lung Dis. 2017;21(5):579-85. Available from: https://doi. org/10.5588/ijtld.16.0518
  8. Bobokhojaev OI, Mahmudzoda IS, Gaibov AG. Faktory riska razvitiya tuberkulyoza v Respublike Tadzhikistan [Risk factors for tuberculosis in the Republic of Tajikistan]. Vestnik Akademii meditsinskikh nauk Tadzhikistana. 2016;2:30-5.
  9. Sanginov AB, Ali-Zade SG, Latiphov MD, Ukumatshoeva LSh. Tuberkulyoz u detey iz ochagov infektsii i chastota ego vyyavleniya [Tuberculosis in children from the focus of infection and the frequency of its detection]. Zdravookhranenie Tadzhikistana. 2017;2:48-52.
  10. Aliev AV. Uklonenie bol'nykh ot lecheniya i effektivnost' khimioterapii [Patient deviation from treatment and effectiveness of chemotherapy]. Vestnik poslediplomnogo obrazovaniya v sfere zdravookhraneniya. 2018;1:102-6.
  11. Peters DH, Adam T, Alonge O, Agyepong IA, Tran N. Implementation research: What it is and how to do it. BMJ. 2013;347:f6753. Available from: https://doi. org/10.1136/bmj.f6753
  12. McNulty M, Smith JD, Villamar J, Burnett-Zeigler I, Vermeer W, Benbow N, et al. Implementation research methodologies for achieving scientific equity and health equity. Ethn Dis. 2019;29(Suppl 1):83-92. Available from: https://doi. org/10.18865/ed.29.S1.83
  13. Gupta-Wright A, Manabe YC. Implementation science: Point-of-care diagnostics in HIV and tuberculosis. Clin Med. 2019;19(2):145-8. Available from: https://doi.org/10.7861/clinmedicine.19-2-145
  14. Cattamanchi A, Berger CA, Shete PB, Turyahabwe S, Joloba M, Moore DA, et al. Implementation science to improve the quality of tuberculosis diagnostic services in Uganda. J Clin Tuberc Other Mycobact Dis. 2019;18:100136. Available from: https://doi.org/10.1016/j.jctube.2019.100136
  15. Hirsch-Moverman Y, Howard AA, Mantell JE, Lebelo L, Frederix K, Wills A, et al. Improving child tuberculosis contact identification and screening in Lesotho: Results from a mixed-methods cluster-randomized implementation science study. PLoS One. 2021;16(5):e0248516. Available from: https://doi. org/10.1371/journal.pone.0248516
  16. Gaydarov GM, Apkhanova NS, Dushina EV. Integral'naya otsenka epidemicheskoy situatsii po tuberkulyozu i vliyanie mediko-organizatsionnykh faktorov na eyo razvitie [The integral estimate of epidemiological situation on tuberculosis and impact of medical organizational factors on its development]. Problemy sotsial'noy gigieny, zdravookhraneniya i istorii meditsiny. 2017;25(3):139-43. Available from: https://doi.org/10.18821/0869-866X-2017-25-3-139-143
  17. Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: The RE-AIM framework. Am J Public Health. 1999;89(9):1322-7. Available from: https://doi.org/10.2105/ajph.89.9.1322
  18. Glasgow RE, Harden SM, Gaglio B, Rabin B, Smith ML, Porter GC, et al. REAIM planning and evaluation framework: Adapting to new science and practice with a 20-year review. Front Public Health. 2019;7:64. Available from: https:// doi.org/10.3389/fpubh.2019.00064
  19. Pinnock H, Barwick M, Carpenter CR, Eldridge S, Grandes G, Griffiths CJ, et al. Standards for Reporting Implementation Studies (StaRI) Statement. BMJ. 2017;356:i6795. Available from: https://doi.org/10.1136/BMJ.I6795
  20. Auer C, Mazitov R, Makhmudov A, Pirmahmadzoda B, Skrahina A, Dobre A, et al. Factors contributing to drug-resistant tuberculosis treatment outcome in five countries in the Eastern Europe and Central Asia region. Monaldi Arch Chest Dis. 2020;90(1). Available from: https://doi.org/10.4081/monaldi. 2020.1235. PMID: 32231347
  21. Migliori GB, Thong PM, Akkerman O, Alffenaar JW, Álvarez-Navascués F, Assao- Neino MM, et al. Worldwide effects of coronavirus disease pandemic on tuberculosis services, January-April 2020. Emerg Infect Dis. 2020;26(11):2709- 2712. Available from: https://doi.org/10.3201/EID2611.203163
  22. Vasilyeva IA, Testov VV, Sterlikov SA. Epidemicheskaya situatsiya po tuberkulyozu v gody pandemii COVID-19 – 2020-2021 gg [Tuberculosis situation in the years of the COVID-19 pandemic – 2020-2021]. Tuberkulyoz i bolezni lyogkikh. 2022;100(3):6-12. Available from: https://doi.org/10.21292/2075-1230-2022- 100-3-6-12
  23. Lienhardt C, Lönnroth K, Menzies D, Balasegaram M, Chakaya J, Cobelens F, et al. Translational кesearch for tuberculosis elimination: Priorities, challenges, and actions. PLoS Med. 2016;13(3):1001965.
  24. Sirodzhidinova UYu, Bobokhojaev OI, Dusmatova ZSh, Mirzoeva FO, Pirov KI, Dzhumaev RR. Analiz situatsii po tuberkulyozu v Respublike Tadzhikistan [Аnalysis of the tuberculosis situation in the Republic of Tajikistan]. Tuberkulyoz i bolezni lyogkikh. 2015;2:39-45.
  25. Korobitsyn A, Bobokhojaev O, Mohr T, Ismoilova J, Makhmudova M, Trusov A. TB case detection in Tajikistan – analysis of existing obstacles. Cent Asian J Glob Heal. 2013;2(2):48.
  26. Alsdurf H, Empringham B, Miller C, Zwerling A. Tuberculosis screening costs and cost-efectiveness in high-risk groups: A systematic review. BMC Infect Dis. 2021;21(1):935. Available from: https://doi.org/10.1186/s12879-021-06633-3
  27. Bobokhojaev O, Mirzoeva F, Brouwer M, Toumanian S, Codlin A. Improving case notification through screening and innovative approaches. WHO, 2016. Good practices in strengthening health systems for the prevention and care of tuberculosis and drug-resistant tuberculosis [cited 2022 May 17]. p. 55-6. Available from: https://www.euro.who.int/__data/assets/pdf_file/0010/298198/Goodpractices- strengthening-HS-prevention-care-TBC-and-drug-resistant-TBC.pdf
  28. Jo Y, Mirzoeva F, Chry M, Qin ZZ, Codlin A, Bobokhojaev O, et al. Standardized framework for evaluating costs of active case-finding programs: An analysis of two programs in Cambodia and Tajikistan. PLoS One. 2020;15(1):e0228216. Available from: https://doi.org/10.1371/journal.pone.0228216
  29. Cardoso-Weinberg A, Alley C, Kupfer LE, Aslanyan G, Makanga M, Zicker F, et al. Funders' perspectives on supporting implementation research in low- and middle-income countries. Glob Health Sci Pract. 2022;10(2):e2100497. Available from: https://doi.org/10.9745/GHSP-D-21-00497

Authors informations:

Tilloeva Zulfiya Khaybulloevna
Head of the Department of Phthisiotherapy, Specialist on Statistics and Infection Prevention and Control, City Center for Protection of Population from Tuberculosis
Researcher ID: AEN-4626-2022
Scopus ID: 57220065383
ORCID ID: 0000-0002-7668-1688
SPIN: 9259-9917
E-mail: ztilloeva@gmail.com

Information about the source of support in the form of grants, equipment, and drugs

The work was carried out as part of the implementation of the National Program for the Protection of the Population from TB for 2021-2025, approved by the Decree of the Government of the Republic of Tajikistan dated February 27, 2021, No. 49. This study was carried out with the support of the “Special Program for Research and Training in the Field of Tropical Diseases”, sponsored by UNICEF, UNDP, the World Bank and WHO. The author did not receive financial support from manufacturers of medicines and medical equipment

Conflict of interest: No conflict

Address for correspondence:

Tilloeva Zulfiya Khaybulloevna
Head of the Department of Phthisiotherapy, Specialist on Statistics and Infection Prevention and Control, City Center for Protection of Population from Tuberculosis

734025, Republic of Tajikistan, Dushanbe, Bukhoro str., 55A

Tel.: +992 (934) 477353

E-mail: ztilloeva@gmail.com

Materials on the topic: